Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.73 USD
-0.07 (-3.89%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.73 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
LXRX 1.73 -0.07(-3.89%)
Will LXRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LXRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LXRX
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
LXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Other News for LXRX
Biotech Alert: Searches spiking for these stocks today
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
Lexicon to face FDA AdCom over diabetes therapy review
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Turnstone Biologics Corp. (TSBX)
Optimized Strategy and Clinical Progress Bolster Buy Rating for Lexicon Pharmaceuticals